Deep vein thrombosis · patients with prevention of deep vein thrombosis1
It is very uncertain whether knee length changes deep vein thrombosis (Fixed‐effect analysis) Venous duplex scan,… compared with thigh length graduated compression stockings (very low certainty).
3 findings from 1 review
OR 1.55 [0.78, 3.07]
3 studies · 496 participants
Very low
OR 1.32 [0.43, 4.06]
3 studies · 496 participants
Very low
no estimate extracted
3 studies · 496 participants
Very low
Minor adverse drug reactions · patients with human Brucellosis
Doxycycline+Rifampicin showed no clear difference in minor adverse drug reactions compared with doxycycline+Streptomycin (low certainty).
1 finding from 1 review
Minor adverse drug reactions · patients with human Brucellosis
It is very uncertain whether doxycycline+Streptomycin changes minor adverse drug reactions compared with doxycycline+Gentamycin (very low certainty).
1 finding from 1 review
Intervention not reported
Retinopathy of prematurity · preterm or low birth weight infants
The intervention showed no clear difference in retinopathy of prematurity (high certainty).
1 finding from 1 review
Minor incontinence to flatus · patients with fissure in ano
Sensitivity Analysis; Stretch may leads to higher minor incontinence to flatus compared with sphincterotomy excluding Marby & Weaver (low certainty).
1 finding from 1 review
Minor incontinence to flatus · patients with fissure in ano
Open showed no clear difference in minor incontinence to flatus compared with closed partial lateral internal sphincterotomy (moderate certainty).
1 finding from 1 review
Minor bleeding · Anticoagulants in ACS
Factor Xa inhibitors showed no clear difference in minor bleeding at 30 days compared with anticoagulants (high certainty).
3 findings from 1 review
RR 0.7 [0.14, 3.39]
2 studies · 20404 participants
High
RR 1.76 [0.52, 5.94]
1 study · 326 participants
Moderate
RR 0.34 [0.28, 0.43]
1 study · 20078 participants
High
The urinary amino telopeptides of collagen I (NTx) (nmol bone collagen equivalents /mmol creatinine) · patients with primary biliary cirrhosis.
1 finding from 1 review
The urinary amino telopeptides of collagen I (NTx) (nmol bone collagen equivalents /mmol creatinine) · patients with primary biliary cirrhosis.
1 finding from 1 review
Overall survival (absolute effect size estimates based on survival rate at 12 months) · participants with advanced hepatocellular carcinoma
It is very uncertain whether pexastimogene devacirepvec (Pexa‐Vec) plus best supportive care changes overall survival (absolute effect size estimates based on survival… compared with best supportive care alone (very low certainty).
1 finding from 1 review
Adverse events considered non‐serious · participants with unresectable hepatocellular carcinoma
It is very uncertain whether adenovirus‐thymidine kinase with ganciclovir (ADV‐TK/GCV) plus liver… changes adverse events considered non‐serious (number of participants) compared with liver transplantation (very low certainty).
1 finding from 1 review
All‐cause mortality · participants with unresectable hepatocellular carcinoma
Double‐dose adenovirus‐thymidine kinase with ganciclovir… may leads to lower all‐cause mortality compared with liver transplantation (low certainty).
1 finding from 1 review
Proportion of people with ≥ 1 serious adverse events during treatment · participants with unresectable hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life · participants with unresectable hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Disease progression · participants with unresectable hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events considered non‐serious · participants with unresectable hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall survival Censored · participants with unresectable hepatocellular carcinoma
It is very uncertain whether recombinant human adenovirus‐p53 and hydroxycamptothecin (rAd‐p53/HCT) changes overall survival Censored compared with hydroxycamptothecin (very low certainty).
1 finding from 1 review
Proportion of people with ≥ 1 serious adverse events · participants with unresectable hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life · participants with unresectable hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Disease progression · participants with unresectable hepatocellular carcinoma
It is very uncertain whether recombinant human adenovirus‐p53 and hydroxycamptothecin (rAd‐p53/HCT) changes proportion of people with disease progression compared with hydroxycamptothecin (very low certainty).
1 finding from 1 review